Compare MasterCard Inc (MA) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasterCard Inc vs Neurocrine Biosciences Inc — how do they compare? MasterCard Inc trades at $574.4 (market cap $499.38B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B). The key difference: MasterCard Inc is far larger — about 34.2× Neurocrine Biosciences Inc's market cap, and MasterCard Inc pays a 0.61% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold MasterCard Inc for 134 Days and Neurocrine Biosciences Inc for 23 Days on average.
| MA | NBIX | |
|---|---|---|
Market Cap | $499.38B | $14.60B |
Volume | 1,862,680 | 1,075,694 |
Sector | Financials | Health |
52-Week High | $599.86 | $185.50 |
52-Week Low | $471.55 | $123.10 |
Typical Hold Time | 134 Days | 23 Days |
Enterprise Value | $512.41B | $14.61B |
Dividend Yield | 0.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mastercard (MA) trades at $574.76, up 1.44% with strong bullish technical signals and consistent earnings beats. The stock shows robust fundamentals with 46.3% net margins and 241.5% ROE, supported by growing institutional interest. Recent news highlights Mastercard's AI and digital payment initiatives, while analyst consensus remains strongly bullish with an $666.67 price target.
Outlook remains positive given earnings momentum and strategic positioning in digital payments, though competition from emerging payment technologies presents a key risk. The stock offers growth potential but requires monitoring of payment industry disruption and macroeconomic factors affecting consumer spending.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
